Eli Lilly’s New Diabetes Pill Shows Promising Results in Landmark Trial

Eli Lilly’s New Diabetes Pill Shows Promising Results In Landmark Trial

In a significant advance in diabetes treatment, drugmaker Eli Lilly said today that its experimental pill, orforglippon, produced dramatic results in a late-stage study — bringing new hope to millions of type 2 diabetes and obesity patients.

The drug, a once-daily tablet, is in the GLP-1 receptor agonist class — the same family as injectable drugs such as Ozempic and Mounjaro — but with an important distinction: it’s oral, no need for needles. This could change treatment adherence and access, especially in areas where injectable treatments are problematic.

A Promising Alternative to Injections
According to the company’s trial data, participants who took the highest dose of orforglipron (36 mg daily) lost an average of 7.9% of their body weight over a 40-week period — equivalent to about 16 pounds. Beyond weight loss, the drug also delivered substantial reductions in HbA1c levels, a key marker for long-term blood sugar control.

“These results are not just statistically significant — they’re clinically meaningful,” said Dr. Jeff Emmick, senior vice president of product development at Eli Lilly. “Orforglipron has the potential to transform how we approach both diabetes and obesity management.”

Global Study, Global Impact
The Phase 3 trial included more than 550 adults across the U.S., India, China, Japan, and Mexico — reflecting Lilly’s commitment to understanding how the drug performs across diverse populations. In India, where over 100 million people live with diabetes, the drug is currently undergoing localized Phase 3 testing against insulin glargine.

Public health experts say the pill’s oral format could be a game changer in developing nations, where fear of needles, limited refrigeration, and healthcare access can hinder injectable use.

Side Effects and Safety
The trial data also underscored a favorable safety profile. The most common side effects were gastrointestinal — including nausea, diarrhea, and vomiting — similar to those seen with other GLP-1 drugs. Notably, orforglipron did not show the liver safety concerns that have dogged some competing medications in this class.

“If confirmed in ongoing studies, this could represent a safer and more convenient alternative to current therapies,” said Dr. Lisa Morales, an endocrinologist at Johns Hopkins University not affiliated with the trial.

What’s Next?
Eli Lilly plans to seek FDA approval for orforglipron’s use in weight management later this year and for diabetes treatment in 2026. Analysts expect the drug to be a commercial blockbuster, potentially capturing a significant share of the $150 billion global obesity treatment market.

The full results of the trial will be presented at the American Diabetes Association’s 83rd Scientific Sessions in June.

With orforglipron, Lilly is doubling down on its leadership in the GLP-1 segment, already riding the success of Mounjaro (tirzepatide). The company’s pipeline for innovation points to a strategic intent not only on treating — but on transforming the landscape of chronic disease management itself.